U.S. stock futures edged higher Tuesday morning, pointing to a potential second day of gains on Wall Street. As investors look to recover from January's down market, digesting more earnings this morning, they also await some economic data, including housing and auto sales and a Senate hearing on proposed new rules on financial reform.

Already on Monday, the tide started turning from January's depressed sentiment following strong manufacturing data and better-than-forecast Exxon Mobil earnings. The Dow industrials, the Nasdaq composite and the S&P 500 all finished more than 1% higher.

Analysts surveyed by Thomson Reuters are looking for life insurance giant MetLife Inc. (MET) to report that its earnings rose 80.0% from a year ago to $0.95 per share for the three months that ended in December. Revenue, however, is expected to total $12.6 billion, which is down 10.1% from a year ago, during a fourth quarter in which it offered guidance and declared a quarterly dividend. The analysts' forecast for the full year calls for earnings of $2.89 per share (-25.7%) on $48.3 billion in revenue (-5.3%). This New York-based insurer's earnings results have been better than expected in three of the past four quarters, beating estimates by as much as 20 cents per share.

MetLife's long-term EPS growth forecast is 10.7%, which is better than that of competitor Prudential Financial Inc. (PRU), and its earnings multiple is 8.8x. The First Call consensus recommendation has been to buy MET for more than 90 days, despite a recent downgrade of the stock. The mean price target is $42.87. Shares have been trading between $32.00 and $40.00 since August and closed the week at $35.32.

Analyst Upgrades

• Canaccord upgraded IBM (IBM) to buy from hold, citing the better-than-expected Q4 report, an ongoing economic recovery and higher IT budgets. The firm raised its target to $150 from $130.
• Citigroup upgraded Archer Daniels Midland (ADM) to buy from hold to reflect strength in the oilseed processing market and a positive inflection in ethanol profitability. The firm raised its target on shares to $37 from $33.
• FBR Capital upgraded Tesco (TESO) to outperform from market perform on expectations the company's top drive orders will accelerate in the coming quarters. The firm raised its target price on shares to $18.
• CBS (CBS) was upgraded to buy from hold at Jefferies.
• HSBC Holdings (HBC) was upgraded to buy from hold at RBS.
• Essex Property Trust (ESS) was upgraded to overweight from equal weight at Barclays.

Analyst Upgrades

• Goldman upgraded 3M Company (MMM) to conviction buy from buy, citing positive global industrial data, underappreciated organic growth and earnings momentum, among other reasons. The firm raised its target to $105 from $100.
• Citigroup upgraded Manpower (MAN) to buy from hold to reflect improvements in the temporary employment sector. The firm raised its target price on shares to $69 from $61.
• Baird upgraded Cerner (CERN) to outperform from neutral and raised its target to $104 from $89 based on Q4 bookings momentum, positive newsflow and reasonable valuation.
• Dow Chemical (DOW) was upgraded to overweight from equal weight at Barclays.
• Magna International (MGA) was upgraded to outperform from market perform at Wells Fargo.

Dow Chemical (DOW - option chain) shares rose Thursday after the company said it will sell its powder coatings business to Netherlands-based Akzo Nobel. Financial terms of the deal were not disclosed, but Dow said it will use the proceeds to reduce its debt. The move is part of Dow's plan to sell noncore assets in order to raise more than $3.5 billion. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on DOW.

DOW opened Thursday morning at $28.20. In morning trading the stock has hit a low of $27.90 and a high of $28.88. As of 12:00, DOW was trading at $28.37 up 1.66 (6.2%). The chart for DOW looks neutral and S&P gives DOW a neutral 3 STARS (out of 5) hold ranking.

TheStreet.com's Jim Cramer says in the wake of an upgrade, FCX has to do a big equity offering.

What will Richard Adkerson do? I can tell you what the CEO of Freeport-McMoRan (NYSE: FCX) (Cramer's Take) ought to do in the wake of the Bank of America-Merrill Lynch upgrade to buy from sell. He ought to do the biggest darned equity offering in history.

I like Richard. He's candid, he's a great copper man, but he spent too much at the high on Phelps Dodge and wasn't prepared when copper prices plummeted as his balance sheet's simply not so hot. So he had to cut his dividend at the bottom, literally at the exact bottom.

Here are some highlights from last week's earnings coverage from BloggingStocks:

• Amgen Inc. (NASDAQ: AMGN) reported strong Q2 earnings thought revenue fell but beat analysts' estimates.
• Colgate-Palmolive Co. (NYSE: CL) beat Q2 earnings estimates but revenue suffered from currency effects.
• Dow Chemical Co. (NYSE: DOW) reported a drop in Q2 revenue and a net loss on restructuring charges.
• Eastman Kodak Co. (NYSE: EK) posted a deeper-than-expected Q2 net loss as sales plunged.
• Exxon Mobil Corp. (NYSE: XOM) reported its lowest quarterly profit in years, well short of expectations.

Pulling off mega deals is always tough. But in the case of Dow Chemical's (NYSE: DOW) acquisition of Rohm & Haas Co., the process was a rollercoaster. Struck before the financial system went into cardiac arrest last year, the transaction resulted in a lawsuit. The main reason was the implosion of Dow's joint venture with a Kuwaiti state-owned company.

Yet, Dow was able to resolve things, albeit with a complex arrangement. The new strategy involved preferred shares, new short-term financings and sales of various divisions, such as the unloading of the Morton Salt unit.

U.S. stock futures climbed higher Thursday morning, indicating stocks may reverse Wednesday's declining trend, as yet another wave of corporate earnings is scheduled for today. Jobless data is also on the docket ahead of the opening bell.

Earnings from some serious heavy weights are scheduled before the market opens, including Exxon Mobil (XOM), Walt Disney Co. (DIS) Motorola (MOT), which reported an unexpected profit, and Dow Chemical (DOW), whose adjusted earnings came in below beat analyst estimates.

Analyst upgrades:

• Baird upgraded WinTrust (NASDAQ: WTFC) to Neutral from Underperform and raised its target to $20 from $13 citing the accretive purchase of AIG (NYSE: AIG) loans and reduced risk of a capital raise.
• Piper Jaffray upgraded Coach (NYSE: COH) to Overweight from Neutral on expectations product sell-throughs and margin trends will improve in the coming quarters. The firm has a $32 target on the stock.
• RBC Capital upgraded Campbell Soup (NYSE: CPB) to Sector Perform from Underperform and raised its target to $33 from $29. The firm cites Campbell's recent innovation, easy volume comps, and "reasonable" consensus estimates for its upgrade.
• Tata Motors (NYSE: TTM) was upgraded to Equal Weight from Underweight at Morgan Stanley.
• Rockwell Automation (NYSE: ROK) was upgraded to Buy from Neutral at BofA/Merrill.
• Fifth Third Bancorp (NASDAQ: FITB) was upgraded to Conviction Buy from Buy at Goldman.

Analyst upgrades:

• Citigroup upgraded Allergan (NYSE: AGN) to Buy from Hold to reflect increased estimates for Botox and its belief Latisse guidance looks conservative. The firm raised its target on shares to $57 from $45.
  
• Jefferies upgraded Texas Instruments (TXN) to Hold from Underperform after channel checks indicated business is strengthening. Jefferies believes Texas Instruments' September quarter guidance will come in better than expected and raised its target on shares to 23 from $16.
  
• FBR Capital upgraded Peabody Energy (BTU) to Outperform from Market Perform to reflect "strong" long-term steel and steam demand trends from China and India. The firm raised its target on shares to $44 from $36.
  
• Elan Corp (ELN) was upgraded to Buy from Neutral at UBS.
  
• Affymetrix (AFFX) was upgraded to Equal Weight from Underweight at Morgan Stanley.
  
• ASML Holding (ASML) was upgraded to Buy from Neutral at BofA/Merrill.

TheStreet.com's Jim Cramer says we should closely monitor the situation as more banks raise capital with equity.

What really did happen Friday? I keep thinking about this because, surely, if you saw how well the Wells Fargo (NYSE: WFC) (Cramer's Take) and Morgan Stanley (NYSE: MS) (Cramer's Take) deals behaved, didn't you, as a bank player, have to presume that there would be and will be more offerings?

If Wells Fargo went up 6, isn't it reasonable to presume that Bank of New York Mellon (NYSE: BK) (Cramer's Take), KeyCorp (NYSE: KEY) (Cramer's Take), Capital One (NYSE: COF) (Cramer's Take), BB&T (NYSE: BBT) (Cramer's Take) and no doubt all of the others, would do the same? Who wouldn't take advantage of this? Fifth Third (NASDAQ: FITB) (Cramer's Take)? Suntrust (NYSE: STI) (Cramer's Take)?

Why did they rally so much?

Analyst upgrades:

• FBR Capital upgraded KBW, Inc (NYSE: KBW) to Market Perform from Underperform as it sees increased capital-raising opportunities for small and mid-sized banks and believes the company's quarter is off to a strong start. The firm raised its target price to $23 from $18.
• Pali Capital upgraded Morgan Stanley (NYSE: MS) to Buy from Neutral on expectations the company's strategic shift towards advisory, distribution and retail will be monetized sooner than expected and its capital markets business is gaining traction. The firm set a $33 target on the stock.
• Baird upgraded Stericycle (NASDAQ: SRCL) to Outperform from Neutral and raised its target to $58 from $55 based on valuation predictable earnings, and its market leading platform.
• Apollo Investment (NYSE: AINV) was raised to Outperform from Market Perform at Keefe Bruyette.
• HSBC Holdings (NYSE: HBC) was lifted at Goldman to Buy from Neutral.
• Dow Chemical (NYSE: DOW) was upgraded to Outperform from Neutral at Credit Suisse.

Dow Chemical (DOW) is raising $1.63 billion by selling common stock. But it really needs more money than that. Perhaps in the current credit market the interest rate it would have had to pay on debt was simply too much.

Reportedly, $1 billion will be used to reduce debt it is taking on to buy rival Rohm and Hass. But the total purchase price of the transaction is $16.5 billion. Dow tried to get out of the deal. The margins in the chemical industry were ruined by the recession, but the document it signed with Rohm & Hass was airtight. Dow will almost certainly end up overpaying and will be burdened with a mammoth debt load in the process.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Baidu Inc. (NASDAQ: BIDU) reported better-than-expected Q1 earnings as revenues surged in the quarter.
• Burger King Holdings Inc. (NYSE: BKC) just beat Q3 expectations despite weak same-store sales growth.
• Corn Products International Inc. (NYSE: CPO) Q1 results were dragged down by higher corn costs.
• Dow Chemical Co. (NYSE: DOW) Q1 earnings sank on falling sales, job cuts and acquisition costs.
• Eastman Kodak Co. (NYSE: EK) reported a deeper-than-expected Q1 loss and suspended its dividend.
• Energizer Holdings Inc. (NYSE: ENR) posted better-than-expected Q2 earnings but revenue declined.